Chimeric Antigen Receptor (CAR) T cell therapy marks a breakthrough in cancer treatment by employing modified T cells to specifically attack cancer cells. While it has shown remarkable potential in treating blood cancers, its effectiveness hinges on precise monitoring of immune responses. Important biomarkers, particularly cytokines such as IL-2 and IFN-γ, are evaluated using immunoassays like ELISA Kits to assess T cell activity and detect adverse effects, such as cytotoxic responses and complications like cytokine release syndrome (CRS). Effective therapy execution requires vigilance in both treatment response and potential complications.
Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment, particularly for blood cancers, by engineering T cells to target cancer-specific antigens.
Effective CAR T cell therapy relies heavily on continuous monitoring of cellular and immune responses to ensure safety and maximize therapeutic benefits.
Key biomarkers, including cytokines such as IL-2 and IFN-γ, are essential for measuring treatment effectiveness and managing risks associated with CAR T cell therapy.
Monitoring immune responses helps clinicians verify CAR T cell expansion, assess therapeutic engagement, and detect adverse effects like cytokine release syndrome early.
Collection
[
|
...
]